doi: 10.1590/S0102-311X2007000700008 41 ThomasBEThiruvengadam KSRKadamDOvungSSivakumarSBala Yogendra ShivakumarSVet al
This interaction is expected to facilitate prolonged retention on the ocular surface [46,47,48,49]
Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors
Disclosures: Emilie Crouchet: Nothing to Disclose, Mayssa DACHRAOUI: Nothing to Disclose, Frank Jhling: Nothing to Disclose, Natascha Roehlen: Nothing to Disclose, Marine Oudot: Nothing to Disclose, Sarah Durand: Nothing to Disclose, Clara Ponsolles: Nothing to Disclose, Clo Gadenne: Nothing to Disclose, Laura Meiss-Heydmann: Nothing to Disclose, Julien Moehlin: Nothing to Disclose, Romain Martin: Nothing to Disclose, Nicolas Brignon: Nothing to Disclose, Fabio Del Zompo: Nothing to Disclose, Yuji Teraoka: Nothing to Disclose, Hiroshi Aikata: Nothing to Disclose, Hiromi Abe-Chayama: Nothing to Disclose, Kazuaki Chayama: Nothing to Disclose, Antonio Saviano: Nothing to Disclose, Danijela Heide: Nothing to Disclose, Emanuele Felli: Nothing to Disclose, Patrick Pessaux: Nothing to Disclose, Mathias Heikenwlder: Nothing to Disclose, Pierre Chambon: Nothing to Disclose, Catherine Schuster: Nothing to Disclose, Joachim Lupberger: Nothing to Disclose, Atish Mukherji: Nothing to Disclose, Thomas Baumert: Nothing to Disclose 445 IMMUNO-METABOLIC DRIVEN HEPATITIS B SURFACE ANTIGEN SEROCONVERSION IN MILD AND SEVERE HEPATITIS B REACTIVATION Jayesh Kumar Sevak 1 MOJAHIDUL ISLAM 1 Gayantika Verma 1 Anoushka Saxena 1 Manoj Sharma 1 Ankur Jindal 1 Varsha Shasthry 1 Syed Naqui Kazim 2 Shiv Kumar Sarin 1 Nirupma Trehanpati 1 , 1 Institute of Liver and Biliary Sciences, 2 Jamia Milia Islamia Background: HBV mediated loss of immune control is the primary cause of HBV reactivation
